URMC Plays Lead Role in Identifying Effective Bladder Cancer Screening Tools
Researchers at URMC are seeking men over the age of 60, with a strong smoking history, to participate in an investigation aimed at improving bladder cancer screening techniques.
Edward Messing, M.D., chair of Urology and a leader of the genitourinary oncology team at the James P. Wilmot Cancer Center, is lead investigator for the NIH- funded study, which also includes University of Texas M.D. Anderson Cancer Center, Baylor College of Medicine, and Laval University in Quebec.
The study focuses on detection of hematuria, a first sign that a tumor may be growing in the bladder, through the use of the Ames Hemastix, a simple, at-home screening tool. There is currently no approved screening method for bladder cancer, one of the most common forms of cancer, particularly among the elderly.
This study aims to confirm promising findings of a preliminary trial in which this test resulted in significantly earlier detection of aggressive bladder cancer, leading to reduced mortality in screening participants compared with unscreened patients.
Study participants will test their urine with the Ames Hemastix daily for two 10-day testing periods – spaced within approximately nine months. A mail-back questionnaire, completed at the beginning of the study, will provide information about participants and their results will be reported after each testing period. Individuals with even a solitary positive test will undergo a thorough urologic evaluation to determine the cause of hematuria; follow-up will continue for two years after completion of the study.
Messing is an expert in the diagnosis and treatment of cancers of the bladder, prostate, kidney and other genitourinary organs. He leads extensive research in the basic biology of bladder and prostate cancers.
For more information
Urology Clinical Trials
Phone: (585) 507-5480
Strong Consult and Transfer Center